Share on StockTwits

Antares Pharma (NASDAQ:ATRS) Director Robert P. Roche, Jr. bought 5,000 shares of the stock on the open market in a transaction that occurred on Wednesday, August 13th. The shares were purchased at an average cost of $1.96 per share, with a total value of $9,800.00. Following the completion of the purchase, the director now directly owns 28,172 shares of the company’s stock, valued at approximately $55,217. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Antares Pharma (NASDAQ:ATRS) traded up 6.90% during mid-day trading on Thursday, hitting $2.17. The stock had a trading volume of 1,496,160 shares. Antares Pharma has a 52-week low of $1.87 and a 52-week high of $5.15. The stock has a 50-day moving average of $2.31 and a 200-day moving average of $3.2. The company’s market cap is $283.1 million.

Antares Pharma (NASDAQ:ATRS) last released its earnings data on Thursday, August 7th. The company reported ($0.07) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.07). The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.43 million. Analysts expect that Antares Pharma will post $-0.24 EPS for the current fiscal year.

Antares Pharma, Inc (NASDAQ:ATRS) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.